Vertex Pharmaceuticals Income Statement (2009-2025) | VRTX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	1,724.30M	1,793.40M	1,984.10M	2,072.60M	2,097.50M	2,196.20M	2,334.30M	2,302.70M	2,374.80M	2,493.20M	2,483.50M	2,517.70M	2,690.60M	2,645.60M	2,771.90M	2,912.00M	2,770.20M	2,964.70M	3,076.40M	3,190.00M
Cost of Revenue (Quarter)	192.30M	228.00M	236.50M	247.40M	245.80M	261.80M	289.40M	283.30M	266.90M	308.60M	318.70M	368.00M	342.60M	371.90M	392.60M	423.40M	363.00M	407.50M	414.80M	466.00M
Gross Profit (Quarter)	1,532.00M	1,565.40M	1,747.60M	1,825.20M	1,851.70M	1,934.40M	2,044.90M	2,019.40M	2,107.90M	2,184.60M	2,164.80M	2,149.70M	2,348.00M	2,273.70M	2,379.30M	2,488.60M	2,407.20M	2,557.20M	2,661.60M	2,724.00M
Operating items
Research & Development (Quarter)	456.00M	448.70M	467.00M	567.80M	601.10M	600.10M	645.00M	694.10M	742.60M	785.70M	810.00M	824.60M	789.10M	966.60M	875.90M	998.70M	979.70M	978.40M	977.70M	973.70M
Selling, General & Administrative (Quarter)	192.10M	194.60M	198.20M	255.20M	215.20M	215.30M	246.80M	267.40M	241.10M	262.60M	263.80M	369.10M	342.70M	372.20M	371.80M	377.60M	396.40M	424.60M	445.10M	487.00M
Restructuring Costs (Quarter)
Other Operating Expenses (Quarter)	188.40M	1,188.00M	264.40M	371.90M	240.30M	274.50M	315.80M	307.70M	612.10M	418.50M	371.60M	335.50M	419.30M	4,821.50M	407.90M	509.70M	764.00M	410.60M	467.40M	523.40M
Operating Expenses (Quarter)	836.50M	1,831.30M	929.60M	1,194.90M	1,056.60M	1,089.90M	1,207.60M	1,269.20M	1,595.80M	1,466.80M	1,445.40M	1,529.20M	1,551.10M	6,160.30M	1,655.60M	1,886.00M	2,140.10M	1,813.60M	1,890.20M	1,984.10M
Operating Income (Quarter)	887.80M	-37.90M	1,054.50M	877.70M	1,040.90M	1,106.30M	1,126.70M	1,033.50M	779.00M	1,026.40M	1,038.10M	988.50M	1,139.50M	-3514.70M	1,116.30M	1,026.00M	630.10M	1,151.10M	1,186.20M	1,205.90M
EBIT (Quarter)	887.80M	-37.90M	1,054.50M	877.70M	1,040.90M	1,106.30M	1,126.70M	1,033.50M	779.00M	1,026.40M	1,038.10M	988.50M	1,139.50M	-3514.70M	1,116.30M	1,026.00M	630.10M	1,151.10M	1,186.20M	1,205.90M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)	1.50M	1.10M	1.10M	1.20M	1.60M	10.80M	46.20M	86.00M	122.60M	144.70M	167.90M	179.50M	181.20M	156.50M	132.20M	128.20M	120.90M	122.40M	125.70M	121.90M
Other Non Operating Income (Quarter)	-52.70M	8.10M	42.40M	7.10M	-72.80M	-78.10M	17.20M	-31.10M	1.30M	1.60M	-15.90M	-9.80M	-31.20M	-23.10M	-16.90M	-14.90M	-17.60M	13.20M	-9.80M	6.50M
Non Operating Income (Quarter)	-52.70M	8.10M	42.40M	7.10M	-72.80M	-78.10M	17.20M	-31.10M	1.30M	1.60M	-15.90M	-9.80M	-31.20M	-23.10M	-16.90M	-14.90M	-17.60M	13.20M	-9.80M	6.50M
Net income details
EBT (Quarter)	820.90M	-44.20M	1,082.80M	870.90M	954.80M	1,024.40M	1,176.40M	1,076.80M	891.50M	1,161.50M	1,179.20M	1,147.60M	1,279.10M	-3391.20M	1,224.10M	1,136.50M	730.40M	1,283.00M	1,298.80M	1,331.00M
Tax Provisions (Quarter)	167.80M	-111.20M	230.90M	100.80M	192.70M	213.90M	245.90M	257.90M	191.70M	245.80M	143.90M	178.80M	179.50M	202.40M	178.70M	223.50M	84.10M	250.10M	215.90M	139.90M
Profit After Tax (Quarter)	653.10M	67.00M	851.90M	770.10M	762.10M	810.50M	930.50M	818.90M	699.80M	915.70M	1,035.30M	968.80M	1,099.60M	-3593.60M	1,045.40M	913.00M	646.30M	1,032.90M	1,082.90M	1,191.10M
Net Income - Minority (Quarter)
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)	653.10M	67.00M	851.90M	770.10M	762.10M	810.50M	930.50M	818.90M	699.80M	915.70M	1,035.30M	968.80M	1,099.60M	-3593.60M	1,045.40M	913.00M	646.30M	1,032.90M	1,082.90M	1,191.10M
Consolidated Net Income (Quarter)	653.10M	67.00M	851.90M	770.10M	762.10M	810.50M	930.50M	818.90M	699.80M	915.70M	1,035.30M	968.80M	1,099.60M	-3593.60M	1,045.40M	913.00M	646.30M	1,032.90M	1,082.90M	1,191.10M
Income towards Parent Company (Quarter)	653.10M	67.00M	851.90M	770.10M	762.10M	810.50M	930.50M	818.90M	699.80M	915.70M	1,035.30M	968.80M	1,099.60M	-3593.60M	1,045.40M	913.00M	646.30M	1,032.90M	1,082.90M	1,191.10M
Net Income towards Common Stockholders (Quarter)	653.10M	67.00M	851.90M	770.10M	762.10M	810.50M	930.50M	818.90M	699.80M	915.70M	1,035.30M	968.80M	1,099.60M	-3593.60M	1,045.40M	913.00M	646.30M	1,032.90M	1,082.90M	1,191.10M
Additional items
EPS (Basic) (Quarter)	2.52	0.26	3.30	3.01	2.99	3.17	3.63	3.19	2.72	3.55	4.01	3.76	4.26	-13.92	4.05	3.53	2.52	4.02	4.24	4.69
EPS (Weighted Average and Diluted) (Quarter)	2.49	0.26	3.28	2.98	2.96	3.13	3.59	3.14	2.69	3.52	3.97	3.71	4.21	-13.92	4.01	3.53	2.49	3.99	4.20	4.64
Shares Outstanding (Weighted Average) (Quarter)	259.40M	259.20M	258.70M	257.70M	255.10M	255.50M	255.80M	256.10M	257.40M	257.60M	258.00M	257.70M	258.20M	258.10M	258.10M	257.90M	256.90M	256.70M	255.60M	255.70M
Shares Outstanding (Diluted Average) (Quarter)	261.90M	261.50M	260.90M	259.90M	257.90M	258.70M	259.50M	259.10M	260.30M	260.40M	260.60M	260.50M	261.10M	258.10M	261.00M	257.90M	259.50M	259.20M	258.60M	258.00M
EBITDA (Quarter)	887.80M	-37.90M	1,054.50M	877.70M	1,040.90M	1,106.30M	1,126.70M	1,033.50M	779.00M	1,026.40M	1,038.10M	988.50M	1,139.50M	-3514.70M	1,116.30M	1,026.00M	630.10M	1,151.10M	1,186.20M	1,205.90M
Interest Expenses (Quarter)										11.20M	10.90M	10.60M	10.40M	9.90M	7.50M	2.80M	3.00M	3.70M	3.30M	3.30M
Tax Rate (Quarter)	20.44%	251.58%	21.32%	11.57%	20.18%	20.88%	20.90%	23.95%	21.50%	21.16%	12.20%	15.58%	14.03%	-5.97%	14.60%	19.67%	11.51%	19.49%	16.62%	10.51%

Research Tools

Vertex Pharmaceuticals Income Statement (2009-2025) | VRTX

Create an account

Sign In

Reset Password